Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 6/20 | 0.63 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SPR | P35270 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14486209 | 0.85 | TP53 (0.52) | DAOTP53HPGDMEN1MAPT | |
| SCHEMBL14486392 | 0.82 | DAO (0.51) | DAOTP53L3MBTL1ALDH1A1 | |
| SCHEMBL14485879 | 0.82 | DAO (0.58) | DAOTP53MAPTL3MBTL1 | |
| SCHEMBL14486303 | 0.82 | DAO (0.55) | DAOTP53HPGDSPRL3MBTL1 | |
| SCHEMBL14486402 | 0.82 | DAO (0.55) | DAOMEN1KMT2AL3MBTL1 | |
| SCHEMBL16001134 | 0.80 | MMP13 (0.49) | DAOTP53HPGDMEN1MAPT | |
| SCHEMBL16001142 | 0.80 | DAO (0.58) | DAOMEN1KMT2AALDH1A1 | |
| SCHEMBL14486312 | 0.80 | DAO (0.55) | DAOTP53HPGDALDH1A1 | |
| SCHEMBL14486090 | 0.79 | DAO (0.59) | DAOHCRTR1HCRTR2ACMSDTP53 | |
| SCHEMBL14486084 | 0.78 | DAO (0.53) | DAOHPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10085986-B2 | Pyrimidinone compounds and their use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-02 | — | — | US | disclosed |
| EP-2729453-B1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL (JP) | 2015-05-06 | — | — | EP | disclosed |
| EP-2729453-B1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL (JP) | 2015-05-06 | — | — | EP | disclosed |
| US-20140248378-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-04 | — | — | US | disclosed |
| US-20140248378-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-04 | — | — | US | disclosed |
| US-20140248378-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-04 | — | — | US | disclosed |
| EP-2729453-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | Takeda Pharmaceutical Company Limited (JP) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013004995-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140248378-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TPMT, DHFR, DPYD | DAO 934/4885HCRTR1 3200/4885HCRTR2 3529/4885 |
| US-10085986-B2 | Pyrimidinone compounds and their use | TPMT, DHFR, DPYD | DAO 934/4885HCRTR1 3200/4885HCRTR2 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.